S'abonner

Translating psoriasis guidelines into practice: Important gaps revealed - 16/02/16

Doi : 10.1016/j.jaad.2015.11.045 
Reva Bhushan, MA, PhD a, , Mark G. Lebwohl, MD b, Alice B. Gottlieb, MD, PhD c, Kevin Boyer, MPH a, Elaine Hamarstrom, PhD a, Neil J. Korman, MD, PhD d, Robert S. Kirsner, MD, PhD e, Arthur J. Sober, MD f, Alan Menter, MD g
a American Academy of Dermatology, Schaumburg, Illinois 
b Mount Sinai Hospital, New York, New York 
c Tufts Medical Center, Boston, Massachusetts 
d University Hospitals Case Medical Center, Cleveland, Ohio 
e University of Miami, Miami, Florida 
f Harvard Medical School, Boston, Massachusetts 
g Baylor University Medical Center, Dallas, Texas 

Reprint requests: Reva Bhushan, MA, PhD, American Academy of Dermatology, 930 E Woodfield Rd, Schaumburg, IL 60173.American Academy of Dermatology930 E Woodfield RdSchaumburgIL60173

Abstract

Background

There is a well-established lack of adherence to evidence-based clinical guidelines. The American Academy of Dermatology (AAD) developed educational sessions entitled Translating Evidence into Practice based on the published guidelines for psoriasis and psoriatic arthritis.

Objective

We sought to determine the effectiveness of Translating Evidence into Practice sessions in improving patient care.

Methods

Pre- and post-session surveys were administered at Translating Evidence into Practice sessions. A follow-up was administered 6 months after completion of the most recent session, which was 2.5 years after the first session.

Results

At both post-session and follow-up, more than 92% of participants believed the sessions had improved their knowledge. The proportion of participants that self-reported assessing disease severity, comorbidities, and quality of life increased at follow-up. Participants' self-reported counseling of patients and confidence in treating psoriasis and psoriatic arthritis also increased at post-session and follow-up. Greater than 97% of participants thought the sessions would have a positive impact on their practice whereas 50% reported making a change in practice.

Limitations

Lack of a control group, the self-reported nature of the data, and potential participant bias are limitations.

Conclusion

The AAD's Translating Evidence into Practice sessions are effective and well received for improving knowledge and practice and can be useful to determine self-reported practice gaps.

Le texte complet de cet article est disponible en PDF.

Key words : assessment of severity, cardiovascular disease, guidelines, metabolic syndrome, practice gaps, psoriasis, psoriatic arthritis, quality of life

Abbreviations used : AAD, PsA, QOL


Plan


 Funding sources: None.
 Disclosure: Dr Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Ferndale, Eli Lilly and Company, Janssen Biotech, LEO Pharmaceuticals, Merz, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Valeant. Dr Gottlieb maintains current consulting/advisory board agreements with Amgen Inc, Astellas, Akros, Centocor (Janssen), Celgene Corp, Bristol Meyers Squibb Co, Beiersdorf Inc, Abbott Labs (Abbvie), TEVA, Actelion, UCB, Novo Nordish, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Eli Lilly and Company, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, Mriji Seika Pharma Co Ltd, Takeda, Mitsubishi, and Tanabe Pharma Development America Inc, Genentech. Dr Korman has served on advisory boards or as a speaker for Abbvie, Amgen, Celgene Corporation, Eli Lilly and Company, Janssen Pharmaceuticals Inc, Novartis Pharmaceuticals Corp, and Pfizer Inc. Dr Menter served as consultant or investigator for Abbott Laboratories, receiving honoraria; served on advisory boards or as a speaker for Abbott Laboratories, AbbVie, Amgen, Astellas Pharma US Inc, Centocor Ortho Biotech Inc, Galderma Laboratories LP, Pfizer Inc, and Warner Chilcott, receiving honoraria or fees; and had or has pending grants from Amgen, Celgene Corporation, Centocor Ortho Biotech Inc, and Pfizer Inc. Drs Bhushan, Hamarstrom, Kirsner, and Sober, and Mr Boyer have no conflicts of interest to declare.


© 2015  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 74 - N° 3

P. 544-551 - mars 2016 Retour au numéro
Article précédent Article précédent
  • Morphological and immunohistochemical clues for the diagnosis of cutaneous leishmaniasis and the interpretation of CD1a status
  • Angel Fernandez-Flores, José Luis Rodriguez-Peralto
| Article suivant Article suivant
  • Intralesional 5-fluorouracil (FU) as a treatment for nonmelanoma skin cancer (NMSC): A review
  • Lauren Metterle, Christopher Nelson, Nishit Patel

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.